Belite Bio, Inc (NASDAQ: BLTE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark Therapeutics, Alkeus Pharmaceuticals, Novartis Pharmaceuticals, Beacon Therapeutics, GenSight Biologics, Ocugen, AbbVie
Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark Therapeutics, Alkeus Pharmaceuticals, Novartis Pharmaceuticals, Beacon Therapeutics, GenSight Biologics, Ocugen, AbbVie